Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578108 | 1.00 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2POLBTDP1 | |
| SCHEMBL578122 | 0.83 | KAT2B (0.51) | NPC1RAB9ASMN1; SMN2POLBTDP1 | |
| SCHEMBL578123 | 0.83 | KAT2B (0.51) | NPC1RAB9ASMN1; SMN2POLBTDP1 | |
| SCHEMBL577712 | 0.80 | RIPK1 (0.44) | KCNN3GAA | |
| SCHEMBL577711 | 0.80 | RIPK1 (0.44) | KCNN3GAA | |
| SCHEMBL27898220 | 0.77 | RIPK1 (0.62) | NPC1RAB9ASMN1; SMN2POLBTDP1 | |
| SCHEMBL578135 | 0.77 | KAT2B (0.40) | — | |
| SCHEMBL578134 | 0.77 | KAT2B (0.40) | — | |
| SCHEMBL14155576 | 0.76 | RIPK1 (0.65) | NPC1RAB9ASMN1; SMN2POLBTDP1 | |
| SCHEMBL28406604 | 0.74 | HDAC6 (0.57) | NPC1RAB9ASMN1; SMN2POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073823-B2 | Compound having hetero ring skeleton, and process for producing optically active compound using the aforementioned compound as asymmetric catalyst | KYOTO UNIVERSITY (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9073823-B2 | Compound having hetero ring skeleton, and process for producing optically active compound using the aforementioned compound as asymmetric catalyst | KYOTO UNIVERSITY (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9073823-B2 | Compound having hetero ring skeleton, and process for producing optically active compound using the aforementioned compound as asymmetric catalyst | KYOTO UNIVERSITY (JP) | 2015-07-07 | — | — | US | disclosed |
| US-8580804-B2 | Compound having hetero ring skeleton, and process for producing optically active compound using the aforementioned compound as asymmetric catalyst | KYOTO UNIVERSITY (JP) | 2013-11-12 | — | — | US | disclosed |
| US-8580804-B2 | Compound having hetero ring skeleton, and process for producing optically active compound using the aforementioned compound as asymmetric catalyst | KYOTO UNIVERSITY (JP) | 2013-11-12 | — | — | US | disclosed |
| US-8580804-B2 | Compound having hetero ring skeleton, and process for producing optically active compound using the aforementioned compound as asymmetric catalyst | KYOTO UNIVERSITY (JP) | 2013-11-12 | — | — | US | disclosed |
| US-20130245257-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130245257-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130245257-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-09-19 | — | — | US | disclosed |
| EP-2418204-B1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | UNIV KYOTO (JP) | 2013-07-24 | — | — | EP | disclosed |
| EP-2418204-B1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | UNIV KYOTO (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-20120095227-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095227-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095227-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2418204-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | Kyoto University (JP) | 2012-02-15 | — | — | EP | disclosed |
| EP-2418204-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | Kyoto University (JP) | 2012-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245257-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | COASY, LSS, INF2 | NPC1 1671/4885RAB9A 1214/4885SMN1; SMN2 3118/4885 |
| US-20120095227-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | CCNL2, ASH2L, AHR | NPC1 4296/4885RAB9A 2308/4885SMN1; SMN2 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.